Thymic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
|
25202099 |
2014 |
Thymic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.
|
24419427 |
2014 |
Thymic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
|
22357254 |
2012 |
Thymic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
KIT is a good molecule marker to differentially diagnose thymic carcinoma from thymoma, while also serving as a predictor of prognosis for TETs.
|
22938452 |
2012 |
Thymic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Considering the need to treat advanced TC more effectively, disparate findings in predictive molecular markers (eg, KIT mutations in TSCC, but not in thymomas) suggest that targeted treatments will have to be different in thymomas and TC.
|
21070984 |
2011 |
Thymic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
|
20970876 |
2011 |
Thymic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apart from their different morphology, TC and thymomas differ also in functional terms (TC, in contrast to thymomas, have lost the capacity to promote the maturation of intratumorous lymphocytes), have different genetic features (discussed in this review), a different immunoprofile (most TC overexpress c-KIT, whereas thymomas are consistently negative), and different clinical features (TC, in contrast to thymomas, are not associated with paraneoplastic myasthenia gravis).
|
20859121 |
2010 |
Thymic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the kit gene have been related to response to imatinib in gastrointestinal stromal tumor and one case report of thymic carcinoma.
|
20651610 |
2010 |
Thymic Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The clinical relevance of KIT mutations is more limited in thymic carcinoma than in GIST as KIT mutations are far less frequent (7% of thymic carcinomas) and are not correlated with KIT expression; furthermore, KIT mutants are not uniformly sensitive to imatinib.
|
20859122 |
2010 |
Thymic Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas.
|
20197733 |
2009 |
Thymic Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
KIT protein was expressed in 88% of the thymic carcinomas and 0% of the thymomas.
|
18448188 |
2008 |
Thymic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
KIT- and CD5-positive staining was observed only in thymic carcinoma.
|
18486988 |
2008 |
Thymic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, COX-2 is expressed in all subtypes of thymomas and thymic carcinomas and thus represents, in addition to EGFR and KIT, a potential therapeutic target.
|
16823844 |
2006 |
Thymic Carcinoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|